Understanding and treating psychosis in young people

Peer reviewed: 
No, item is not peer reviewed.
Scholarly level: 
Faculty/Staff
Final version published as: 

Schwartz, C., Waddell, C., Barican, J., Garland, O., Nightingale, L., & Gray-Grant,D. (2009). Understanding and treating psychosis in young people. Children’s Mental Health Research Quarterly, 3(3), 1–24. Vancouver, BC: Children’s Health Policy Centre, Faculty of Health Sciences, Simon Fraser University.

https://childhealthpolicy.ca/wp-content/uploads/2012/12/RQ-3-09-Summer.pdf

Date created: 
2009
Abstract: 

Background: Medications are a key treatment for young people with psychosis. In fact, up to 80% of individuals will experience a remission of psychotic symptoms within their first year of treatment with antipsychotic medication. Given the array of antipsychotics available, we set to determine which of these medications provide the best outcomes for youth considering both effectiveness and side effect profiles.  

Methods: We used systematic review methods to identify randomized controlled trial (RCT) evaluations of interventions for psychosis. Applying our inclusion criteria, we accepted seven RCTs evaluating 6 medications.

Results: The medications clozapine, haloperidol, olanzapine and risperidone proved successful in treating psychosis in young people. However, due to clozapine’s side effect profile, it is typically reserved for youth who have not responded to at least two other antipsychotics. When price is a consideration, older antipsychotic have the benefit of costing less while having similar effectiveness to newer medications. 

Conclusions: With careful management, antipsychotic medications can dramatically improve functioning and reduce suffering for youth with psychosis.

Language: 
English
Rights: 
You are free to copy, distribute and transmit this work under the following conditions: You must give attribution to the work (but not in any way that suggests that the author endorses you or your use of the work); You may not use this work for commercial purposes; You may not alter, transform, or build upon this work. Any further uses require the permission of the rights holder (or author if no rights holder is listed). These rights are based on the Creative Commons Attribution-NonCommercial-NoDerivatives License.
Statistics: